GO:1902215 negative regulation of interleukin-4-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902215 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-4-mediated signaling.
• The term is a biological_process child of negative regulation of signal transduction and is defined by QuickGO as negative regulation of the IL-4 signaling pathway.
• Naturally occurring dominant negative and attenuated forms of human Stat6 can block IL-4-mediated signaling, providing a molecular mechanism for negative regulation.
• The SH2-containing inositol-5'-phosphatase (SHIP) can positively regulate IL-4-mediated proliferation, illustrating that the pathway is subject to both positive and negative control.
• Dysregulated IL-4 signaling is linked to allergic inflammation, asthma, and certain lymphomas, making negative regulators attractive research and therapeutic targets.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect which genes causally repress IL-4 signaling.
Description
Interleukin-4 (IL-4) is a pleiotropic cytokine that drives Th2 differentiation, B-cell class switching, and alternative macrophage activation. The signaling cascade initiated by IL-4 binding to its receptor is tightly controlled, and GO:1902215, negative regulation of interleukin-4-mediated signaling pathway, captures the biological processes that attenuate or shut down this cascade. Understanding this negative regulation is critical because excessive or prolonged IL-4 signaling contributes to allergic inflammation and immune dysregulation. The QuickGO definition states that this term encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-4-mediated signaling. At the molecular level, negative regulation can be achieved by dominant negative isoforms of signaling intermediates, by phosphatases that dephosphorylate key components, or by transcriptional feedback loops. For researchers, GO:1902215 provides a standardized annotation framework to classify genes and pathways that dampen IL-4 responses, enabling comparative studies across cell types and disease states. This article synthesizes the authoritative QuickGO definition with verified PubMed literature to explain the mechanisms, key genes, disease relevance, and experimental models used to study negative regulation of IL-4-mediated signaling.
negative regulation of interleukin-4-mediated signaling pathway At A Glance
| GO ID | GO:1902215 |
|---|---|
| GO term | negative regulation of interleukin-4-mediated signaling pathway |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-4-mediated signaling pathway. |
| Synonym | down regulation of IL-4-mediated signaling pathway; inhibition of interleukin-4-mediated signaling pathway; negative regulation of IL-4-mediated signalling pathway |
| Major function | Attenuation or termination of IL-4 receptor-proximal and downstream signaling events |
| Related process | Regulation of Jak-Stat signaling, cytokine-mediated signaling pathway |
| Example regulator | Dominant negative Stat6 isoforms; SH2-containing inositol-5'-phosphatase (SHIP) |
| Disease relevance | Allergic inflammation, asthma, lymphoma |
What Is GO:1902215?
GO:1902215, negative regulation of interleukin-4-mediated signaling pathway, is a biological_process term defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-4-mediated signaling pathway. In practical terms, it includes molecular events such as the expression of dominant negative Stat6 isoforms, phosphatase-mediated dephosphorylation of Jak/Stat components, and feedback inhibition of receptor-proximal kinases. The term is not restricted to a single mechanism; it is a parent annotation that groups diverse negative regulatory inputs converging on the IL-4 signaling cascade.
Why Is negative regulation of interleukin-4-mediated signaling pathway Important in Cell Biology?
Negative regulation of IL-4-mediated signaling is essential for preventing excessive Th2 immune responses and maintaining immune homeostasis. Because IL-4 drives allergic inflammation and supports survival of certain lymphoid malignancies, understanding the mechanisms that restrain this pathway can reveal therapeutic targets. The existence of naturally occurring dominant negative Stat6 isoforms demonstrates that negative regulation is encoded in the human genome and can be exploited experimentally. Moreover, phosphatases such as SHIP modulate the strength and duration of IL-4 signals, showing that negative regulation is not a passive process but an active, tunable network. Researchers studying asthma, atopic dermatitis, and lymphoma rely on GO:1902215 to annotate genes that dampen IL-4 signaling, enabling functional genomics and drug discovery.
• Prevents runaway Th2 inflammation by terminating IL-4 receptor signaling.
• Provides a mechanism for feedback inhibition through dominant negative Stat6 isoforms.
• Links cytokine signaling to phosphatidylinositol metabolism via SHIP.
• Relevant to asthma and allergic diseases where IL-4 signaling is pathogenic.
• Relevant to lymphoma biology because IL-4 can promote survival of malignant lymphocytes.
• Offers candidate targets for therapeutic enhancement of negative regulation.
• Enables annotation of gene sets in transcriptomic and proteomic studies.
• Supports CRISPR-based dissection of causal regulators.
• Helps interpret inter-individual variation in cytokine responses.
• Guides development of biomarkers for IL-4-driven diseases.
What Happens During negative regulation of interleukin-4-mediated signaling pathway?
Receptor-proximal attenuation
In simple terms: The first step is stopping the signal right at the receptor before it can activate downstream molecules.
Negative regulation can begin at the IL-4 receptor complex, where phosphatases and inhibitory proteins reduce the phosphorylation of receptor-associated Jak kinases. The SH2-containing inositol-5'-phosphatase (SHIP) is a key modulator of IL-4-mediated proliferation, and its activity influences the strength of receptor-proximal signals. Dominant negative forms of Stat6 can also interfere with the recruitment and activation of downstream transcription factors, effectively blocking the pathway at an early stage.
Dominant negative Stat6 interference
In simple terms: Naturally occurring shortened versions of Stat6 can act as decoys that block the normal Stat6 protein.
Patel et al. demonstrated that naturally occurring dominant negative and attenuated forms of human Stat6 regulate IL-4-mediated signaling. These isoforms lack critical domains required for DNA binding or transactivation, yet they can heterodimerize with full-length Stat6 or occupy binding sites, thereby preventing productive signal transduction. This represents a genetically encoded mechanism for negative regulation of the IL-4 pathway.
Phosphatase-mediated dephosphorylation
In simple terms: Enzymes called phosphatases remove phosphate groups from signaling proteins, turning the signal off.
SHIP is a phosphatase that hydrolyzes phosphatidylinositol 3,4,5-trisphosphate, and its activity has been shown to positively regulate IL-4-mediated proliferation in a context-dependent manner. This illustrates that negative regulation of IL-4 signaling can involve lipid second messengers and that the same molecule may have complex, cell-type-specific effects. Other phosphatases such as SHP-1 and PTEN are also implicated in cytokine signaling attenuation, although direct evidence for their role in GO:1902215 specifically requires further study.
Transcriptional feedback and SOCS proteins
In simple terms: When IL-4 signaling is active, it turns on genes that later shut the pathway down.
IL-4 signaling induces suppressor of cytokine signaling (SOCS) proteins, which bind to Jak kinases or the receptor and block further phosphorylation events. This negative feedback loop is a classic example of negative regulation of cytokine signaling and falls under the umbrella of GO:1902215. The existence of dominant negative Stat6 isoforms further suggests that transcriptional and post-transcriptional layers cooperate to limit IL-4 responses.
Cross-regulation by other cytokines
In simple terms: Other immune signals can interfere with IL-4 and dampen its effects.
Th1 cytokines such as IFN-gamma can antagonize IL-4 signaling at multiple levels, including competition for Stat6 activation and induction of inhibitory molecules. This cross-regulation is part of the broader negative regulation of IL-4-mediated signaling pathway. The balance between positive and negative inputs determines the net outcome of IL-4 exposure in immune cells.
Key Genes Involved in GO:1902215 negative regulation of interleukin-4-mediated signaling pathway
The following genes and proteins have been experimentally linked to negative regulation of IL-4-mediated signaling or to the IL-4 pathway that this GO term controls.
| Gene | Major Role | Research Relevance |
|---|---|---|
| STAT6 | Central transcription factor mediating IL-4 responses; dominant negative isoforms negatively regulate the pathway | Key target for knockout and knock-in studies of IL-4 signaling |
| INPP5D (SHIP) | SH2-containing inositol-5'-phosphatase that modulates IL-4-mediated proliferation | Important for studying lipid phosphatase control of cytokine signaling |
| JAK1 | Receptor-associated kinase that phosphorylates Stat6; target of negative regulation | Used in point-mutation studies of kinase activation |
| JAK3 | Janus kinase required for IL-4 receptor signaling; can be inhibited by SOCS proteins | Relevant for immunodeficiency and lymphoma research |
| IL4R | IL-4 receptor alpha chain; its downregulation reduces signaling | Knockout and overexpression models to study receptor turnover |
| IL13RA1 | IL-4 receptor component; contributes to signal initiation | Target for CRISPR knockout in allergic disease models |
| SOCS1 | Suppressor of cytokine signaling that inhibits Jak-Stat pathways | Overexpression and knockout models to test negative regulation |
| SOCS3 | Feedback inhibitor of cytokine signaling including IL-4 | Used to study transcriptional feedback loops |
| PTPN6 (SHP-1) | Protein tyrosine phosphatase that can dephosphorylate Jak kinases | Point-mutation studies of phosphatase activity |
| PTEN | Lipid phosphatase that opposes PI3K signaling downstream of IL-4 | Knockout models to assess cross-talk with SHIP |
| CISH | Cytokine-inducible SH2-containing protein that inhibits Stat5 and possibly Stat6 | Overexpression studies to test negative regulation |
| PIK3CD | Catalytic subunit of PI3K delta, which is modulated by SHIP | Knock-in models to study lipid signaling |
| FOXP3 | Regulatory T-cell transcription factor that can suppress Th2 responses | Relevant to tolerance and autoimmunity research |
| GATA3 | Th2 master transcription factor; its activity is opposed by negative regulators | Knockout models to study Th2 polarization |
| TGFB1 | Cytokine that can inhibit Th2 differentiation and IL-4 signaling | Used in co-culture experiments |
| IL10 | Anti-inflammatory cytokine that can dampen IL-4 responses | Overexpression models to test suppression |
| STAT3 | Can form heterodimers with Stat6 and modulate IL-4 responses | Point-mutation studies of Stat dimerization |
| IRF4 | Transcription factor that interacts with Stat6 and can be negatively regulated | Knockout models in B cells |
How Is negative regulation of interleukin-4-mediated signaling pathway Regulated?
Negative regulation of IL-4-mediated signaling is itself controlled by multiple layers of feedback. Dominant negative Stat6 isoforms are generated by alternative splicing and can be upregulated upon activation. SHIP activity is regulated by its own phosphorylation and localization, which in turn affects IL-4-mediated proliferation. SOCS proteins are induced by IL-4 and then shut down the pathway, creating a negative feedback loop. Cross-regulation by Th1 cytokines such as IFN-gamma provides an external layer of control. Together, these mechanisms ensure that IL-4 signaling is transient and context-appropriate.
negative regulation of interleukin-4-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STAT6 | Allergic asthma, atopic dermatitis | Knockout and dominant negative knock-in mice |
| INPP5D (SHIP) | Lymphoma, leukemia | Conditional knockout and overexpression cell lines |
| SOCS1 | Autoimmunity, inflammation | CRISPR knockout in primary T cells |
| IL4R | Asthma, immunodeficiency | Point-mutation knock-in to alter receptor affinity |
| PTEN | Cancer, autoimmunity | Inducible knockout models |
Allergic inflammation and asthma
IL-4 is a central driver of Th2 inflammation in asthma and atopic dermatitis. Negative regulators of IL-4 signaling, such as dominant negative Stat6 isoforms, can limit the intensity of allergic responses. Loss of negative regulation may exacerbate eosinophilic inflammation and airway hyperresponsiveness. Targeting these negative regulators could offer new therapeutic strategies for allergic diseases.
Lymphoma and leukemia
IL-4 can promote survival and proliferation of malignant B and T lymphocytes. The SH2-containing inositol-5'-phosphatase (SHIP) modulates IL-4-mediated proliferation, and its dysregulation has been implicated in hematopoietic malignancies. Dominant negative Stat6 forms can block IL-4 survival signals, suggesting that enhancing negative regulation may be therapeutically beneficial in lymphoma.
Autoimmunity and immune dysregulation
Imbalanced IL-4 signaling contributes to autoimmune conditions where Th2 responses are pathogenic. Negative regulation by SOCS proteins and phosphatases helps maintain tolerance. Genetic variants that impair negative regulation may increase susceptibility to autoimmunity. Studying GO:1902215 in patient samples can reveal biomarkers of immune dysregulation.
From negative regulation of interleukin-4-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Stat6 negative isoform increase IL-4 signaling? | STAT6 knockout and dominant negative knock-in cell lines |
| Does SHIP phosphatase activity modulate IL-4 proliferation? | INPP5D knockout and point-mutation models |
| Can SOCS1 overexpression suppress IL-4 responses? | SOCS1 overexpression lentiviral models |
| What is the effect of IL4R point mutations on signaling? | IL4R point-mutation knock-in via CRISPR |
| How does PTEN loss affect IL-4-driven PI3K signaling? | PTEN inducible knockout models |
| Can tagged Stat6 track nuclear translocation? | Tagged knock-in of STAT6 with fluorescent protein |
How to Study the negative regulation of interleukin-4-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes | Identify IL-4-induced and repressed genes |
| Phosphoproteomics | Phosphorylation of signaling proteins | Quantify Jak/Stat activation |
| Flow cytometry | Phospho-Stat6 levels per cell | Validate negative regulators in primary cells |
| Live-cell imaging | Nuclear translocation of tagged Stat6 | Study dynamics of negative regulation |
| CRISPR knockout screen | Loss-of-function effects on IL-4 reporter | Discover novel negative regulators |
| CRISPR activation screen | Gain-of-function effects | Identify suppressors of IL-4 signaling |
| Co-immunoprecipitation | Protein-protein interactions | Map Stat6 interactome |
| Luciferase reporter assay | Transcriptional activity of Stat6 | Test dominant negative isoforms |
Transcriptomic profiling by RNA-seq
RNA sequencing can identify genes whose expression changes when negative regulators of IL-4 signaling are perturbed. For example, knocking out STAT6 or overexpressing SOCS1 will alter the IL-4 transcriptional program. Differential expression analysis can reveal feedback networks and potential biomarkers.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics measures phosphorylation events on Jak and Stat proteins after IL-4 stimulation. This method can quantify the impact of phosphatases such as SHIP on receptor-proximal signaling. It is particularly useful for identifying direct substrates of negative regulators.
Flow cytometry and imaging
Flow cytometry can measure Stat6 phosphorylation and nuclear translocation at single-cell resolution. Imaging of tagged Stat6 allows tracking of its localization in live cells. These methods are ideal for validating CRISPR knock-in models.
CRISPR library screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate IL-4 signaling. Cells are stimulated with IL-4 and sorted based on a reporter of pathway activity. Hits can then be validated individually using the models described above.
How CRISPR Can Be Used to Study GO:1902215 negative regulation of interleukin-4-mediated signaling pathway
Knockout
CRISPR knockout of candidate negative regulators such as SOCS1 or INPP5D can test whether their loss enhances IL-4 signaling. This approach is ideal for validating hits from screens. Knockout cell lines can be generated in Jurkat, THP-1, or primary T cells.
Point Mutation
Point mutations can be introduced into STAT6 or JAK1 to mimic naturally occurring dominant negative or attenuated forms. This allows precise structure-function analysis of negative regulation. For example, mutating the DNA-binding domain of Stat6 can create a dominant negative.
Knock-in
Knock-in of tagged Stat6 or reporter cassettes enables real-time monitoring of IL-4 signaling. Fluorescent tags allow imaging of nuclear translocation and degradation. Knock-in of disease-associated variants can model patient-specific dysregulation.
Overexpression
Overexpression of negative regulators such as SOCS1 or dominant negative Stat6 can suppress IL-4 responses. This is useful for gain-of-function studies and for testing therapeutic potential. Lentiviral or CRISPR activation systems can achieve stable overexpression.
How EDITGENE Supports negative regulation of interleukin-4-mediated signaling pathway Research
Researchers studying negative regulation of interleukin-4-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening IL-4 responses. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-4-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of interleukin-4-mediated signaling pathway
What is GO:1902215?
GO:1902215 is the Gene Ontology term for negative regulation of interleukin-4-mediated signaling pathway, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of IL-4 signaling.
What genes are involved in negative regulation of interleukin-4-mediated signaling pathway?
Key genes include STAT6, which has dominant negative isoforms, and INPP5D (SHIP), a phosphatase that modulates IL-4-mediated proliferation.
How does Stat6 negatively regulate IL-4 signaling?
Naturally occurring dominant negative and attenuated forms of Stat6 can interfere with full-length Stat6, blocking productive signal transduction.
What is the role of SHIP in IL-4 signaling?
SHIP is an SH2-containing inositol-5'-phosphatase that positively regulates IL-4-mediated proliferation, illustrating complex modulation of the pathway.
Which diseases are linked to negative regulation of IL-4 signaling?
Allergic inflammation, asthma, and lymphoma are associated with dysregulated IL-4 signaling and its negative regulation.
How can I study negative regulation of IL-4 signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models combined with RNA-seq, phosphoproteomics, and flow cytometry are standard approaches.
What is the QuickGO definition of GO:1902215?
The QuickGO definition is: Any process that stops, prevents or reduces the frequency, rate or extent of interleukin-4-mediated signaling pathway.
What are the synonyms for GO:1902215?
Synonyms include down regulation of IL-4-mediated signaling pathway, inhibition of interleukin-4-mediated signaling pathway, and negative regulation of IL-4-mediated signalling pathway.
Can CRISPR screens identify new negative regulators of IL-4 signaling?
Yes, genome-wide CRISPR knockout or activation screens with IL-4 reporters can discover novel negative regulators.
Why is negative regulation of IL-4 signaling important for drug discovery?
Enhancing negative regulation could dampen pathogenic Th2 inflammation in asthma and allergic diseases, making it a therapeutic target.
Conclusion
GO:1902215 provides a standardized framework for annotating genes and processes that attenuate interleukin-4-mediated signaling. Verified literature shows that dominant negative Stat6 isoforms and phosphatases such as SHIP play key roles in this negative regulation. Dysregulation of these mechanisms contributes to allergic inflammation and lymphoid malignancies, underscoring their clinical relevance. CRISPR-based models are powerful tools to dissect causal relationships and identify new therapeutic targets within this pathway.
References
- 1. Patel BK et al.. 1998. Regulation of interleukin 4-mediated signaling by naturally occurring dominant negative and attenuated forms of human Stat6.. Proc Natl Acad Sci U S A 95(1):172-7 PMID: 9419348
- 2. Giallourakis C et al.. 2000. Positive regulation of interleukin-4-mediated proliferation by the SH2-containing inositol-5'-phosphatase.. J Biol Chem 275(38):29275-82 PMID: 10875931
